- Home
- PLX vs UNCY Comparison
PLX vs UNCY Comparison
Compare PLX & UNCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PLX | UNCY |
|---|---|---|
| Founded | 1993 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 142.3M | 126.4M |
| IPO Year | 1998 | 2021 |
Fundamental Metrics
Financial Performance| Metric | PLX | UNCY |
|---|---|---|
| Price | $1.79 | $6.05 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | $12.00 | ★ $44.50 |
| AVG Volume (30 Days) | ★ 586.0K | 351.2K |
| Earning Date | 11-13-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.07 | N/A |
| Revenue | ★ $61,840,000.00 | N/A |
| Revenue This Year | $14.29 | N/A |
| Revenue Next Year | $16.65 | N/A |
| P/E Ratio | $25.77 | ★ N/A |
| Revenue Growth | ★ 35.41 | N/A |
| 52 Week Low | $1.32 | $3.71 |
| 52 Week High | $3.10 | $11.00 |
Technical Indicators
Market Signals| Indicator | PLX | UNCY |
|---|---|---|
| Relative Strength Index (RSI) | 47.81 | 54.75 |
| Support Level | $1.72 | $5.36 |
| Resistance Level | $1.84 | $5.95 |
| Average True Range (ATR) | 0.08 | 0.34 |
| MACD | 0.01 | -0.03 |
| Stochastic Oscillator | 41.38 | 72.63 |
Price Performance
Historical ComparisonAbout PLX Protalix BioTherapeutics Inc. (DE)
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.
About UNCY Unicycive Therapeutics Inc.
Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's manufactures drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury. Company's pipeline comprised of two product candidates: Oxylanthanum Carbonate and UNI-494.